OSE Pharma SA Cash Flow Conversion Efficiency
OSE Pharma SA cash flow conversion efficiency. Based on the latest financial reports, OSE Pharma SA (OSE) has a cash flow conversion efficiency ratio of -0.355x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.98 Million ≈ $-21.02 Million USD) by net assets (€50.60 Million ≈ $59.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OSE Pharma SA (2012–2024)
Cash flow conversion efficiency of OSE Pharma SA from 2012 to 2024. This chart illustrates how OSE Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OSE stock price and chart for real-time trading data and today's change.
OSE Pharma SA Cash Flow Conversion Ratio Explained
OSE Pharma SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OSE Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSE Pharma SA ranked by their cash flow conversion efficiency. Also see OSE Pharma SA stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Caprice Resources Ltd
AU:CRS
|
-0.023x |
|
Econpile Holdings Bhd
KLSE:5253
|
0.006x |
|
Electra Battery Materials Corp
NASDAQ:ELBM
|
-0.038x |
|
Pyxis Tankers Inc
NASDAQ:PXS
|
0.033x |
|
Arizona Gold & Silver Inc.
V:AZS
|
-0.042x |
|
FFI Holdings Ltd
AU:FFI
|
-0.121x |
|
Sungchang Hold
KO:000180
|
-0.004x |
|
NEORIGIN Co. Ltd
KQ:094860
|
-0.069x |
Annual Cash Flow Conversion Efficiency for OSE Pharma SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of OSE Pharma SA from 2012 to 2024. Review how much free cash does OSE Pharma SA generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €63.81 Million ≈ $74.60 Million |
€48.44 Million ≈ $56.63 Million |
0.759x | +188.24% |
| 2023-12-31 | €22.98 Million ≈ $26.86 Million |
€-19.76 Million ≈ $-23.11 Million |
-0.860x | -53.40% |
| 2022-12-31 | €32.55 Million ≈ $38.05 Million |
€-18.25 Million ≈ $-21.34 Million |
-0.561x | -168.75% |
| 2021-12-31 | €47.53 Million ≈ $55.57 Million |
€-9.92 Million ≈ $-11.60 Million |
-0.209x | +34.64% |
| 2020-12-31 | €61.24 Million ≈ $71.59 Million |
€-19.55 Million ≈ $-22.86 Million |
-0.319x | -308.16% |
| 2019-12-31 | €58.49 Million ≈ $68.38 Million |
€8.97 Million ≈ $10.49 Million |
0.153x | +779.40% |
| 2018-12-31 | €61.75 Million ≈ $72.20 Million |
€1.08 Million ≈ $1.26 Million |
0.017x | +112.09% |
| 2017-12-31 | €55.45 Million ≈ $64.82 Million |
€-8.00 Million ≈ $-9.35 Million |
-0.144x | -1460.42% |
| 2016-12-31 | €64.53 Million ≈ $75.44 Million |
€684.00K ≈ $799.67K |
0.011x | +103.33% |
| 2015-12-31 | €14.48 Million ≈ $16.92 Million |
€-4.61 Million ≈ $-5.39 Million |
-0.319x | -113.21% |
| 2014-12-31 | €-803.00K ≈ $-938.79K |
€-1.94 Million ≈ $-2.26 Million |
2.412x | +783.11% |
| 2013-12-31 | €-864.00K ≈ $-1.01 Million |
€-236.00K ≈ $-275.91K |
0.273x | -87.59% |
| 2012-12-31 | €-633.00K ≈ $-740.04K |
€-1.39 Million ≈ $-1.63 Million |
2.201x | -- |
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more